MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Telmisartan Versus Amlodipine in Patients With Mild-to-Moderate Hypertension

Phase 3
Completed
Conditions
Hypertension
Interventions
Device: Amlodipine
Drug: Placebo
First Posted Date
2014-06-27
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
431
Registration Number
NCT02177409

Telmisartan Compared With Enalapril in Elderly Patients With Blood Hypertension

Phase 4
Completed
Conditions
Hypertension
Interventions
First Posted Date
2014-06-27
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
374
Registration Number
NCT02177461

Pramipexole in Untreated and Levodopa-treated Parkinson's Disease Patients

Phase 3
Completed
Conditions
Parkinson Disease
Interventions
Drug: Placebo
First Posted Date
2014-06-27
Last Posted Date
2014-06-27
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
150
Registration Number
NCT02177357

Dose Tolerance Study After Ocular Administration of Tiotropium in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: 0.28 mcg tiotropium solution
Drug: 0.40 mcg tiotropium solution
Drug: 0.02 mcg tiotropium solution
Drug: 0.08 mcg tiotropium solution
Drug: 0.16 mcg tiotropium solution
Drug: 0.04 mcg tiotropium solution
Drug: Placebo solution
First Posted Date
2014-06-27
Last Posted Date
2014-06-27
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
48
Registration Number
NCT02177305

Tiotropium in the Treatment of the Patients With Chronic Obstructive Pulmonary Disease

Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
First Posted Date
2014-06-27
Last Posted Date
2014-06-27
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
3588
Registration Number
NCT02177318
Locations
🇯🇵

Boehringer Ingelheim Investigational Site, Yurihonjou, Japan

MICARDIS® and Valsartan in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring

Phase 3
Completed
Conditions
Hypertension
Interventions
Drug: Placebo
First Posted Date
2014-06-27
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
426
Registration Number
NCT02177396

Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease

Phase 3
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Placebo Inhalation solution
Drug: Placebo Inhalation Aerosol
First Posted Date
2014-06-27
Last Posted Date
2014-06-27
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1118
Registration Number
NCT02177253

Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients

Phase 1
Completed
Conditions
Hepatitis C, Chronic
Interventions
Drug: Placebo
First Posted Date
2014-06-27
Last Posted Date
2016-06-06
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
75
Registration Number
NCT02176525

Lacidipine in Medical Practice in Patients With Mild to Moderate Essential Hypertension

Phase 3
Completed
Conditions
Hypertension
Interventions
First Posted Date
2014-06-27
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
53
Registration Number
NCT02177331

Efficacy and Safety of Chronic Administration of Telmisartan as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension

Phase 3
Completed
Conditions
Hypertension
Interventions
First Posted Date
2014-06-27
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
489
Registration Number
NCT02177422
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy